BiotechTube

Tamsulosin OCAS

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

Conditions

Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

Trial Timeline

Mar 1, 2013 → Jan 1, 2015

NCT ID
NCT02180789

About Tamsulosin OCAS

Tamsulosin OCAS is a approved stage product being developed by Astellas Pharma for Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH). The current trial status is completed. This product is registered under clinical trial identifier NCT02180789. Target conditions include Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH).

What happened to similar drugs?

4 of 13 similar drugs in Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) were approved

Approved (4) Terminated (1) Active (8)
✅Tamsulosin + SolifenacinAstellas PharmaApproved
✅Tamsulosin + SolifenacinAstellas PharmaApproved
✅GabapentinPfizerApproved
✅CiprofloxacinIterum TherapeuticsApproved
🔄tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
🔄DuloxetineShionogiPhase 3
🔄Duloxetine + PlaceboShionogiPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02180789ApprovedCompleted

Competing Products

20 competing products in Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

See all competitors
ProductCompanyStageHype Score
JSP191Jasper TherapeuticsPhase 1
11
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
35
SolifenacinAstellas PharmaPre-clinical
26
Tamsulosin + SolifenacinAstellas PharmaApproved
43
Vesitirim™ (Solifenacin)Astellas PharmaPre-clinical
26
Mirabegron + PlaceboAstellas PharmaPhase 2
35
tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
tamsulosin hydrochloride + solifenacin succinate + PlaceboAstellas PharmaPhase 2
35
Tamsulosin + SolifenacinAstellas PharmaApproved
43
DuloxetineShionogiPhase 3
40
Duloxetine + PlaceboShionogiPhase 3
40
AZD1656AstraZenecaPhase 1
29
Nirsevimab + PlaceboAstraZenecaPhase 3
44
RSVpreF + PlaceboPfizerPhase 3
44
GabapentinPfizerApproved
43
Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusionBristol Myers SquibbPre-clinical
30
ALX-0171 1.5 mg/kgSanofiPhase 2
27
ALX-0171 3.0 mg/kg + ALX-0171 6.0 mg/kg + ALX-0171 9.0 mg/kgSanofiPhase 2
35
ALX-0171 Dose 1 + ALX-0171 Dose 2 + PlaceboSanofiPhase 2
27
Placebo + Hydrocodone bitartrateUCBPhase 3
40